ProCE Banner Activity

Treating Brain Metastases in HER2-Positive Breast Cancer: Progress at Last!

Clinical Thought
Sara Tolaney, MD, MPH, reviews recent clinical trial data showing survival benefits from newer targeted agents in the setting of HER2-positive, advanced breast cancer with brain metastases.

Released: January 03, 2023

Expiration: January 02, 2024

Share

Faculty

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

AstraZeneca

Daiichi Sankyo, Inc.

Puma Biotechnology, Inc.

Seagen Inc.

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Sara Tolaney, MD, MPH: research (paid to institution): AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech/Roche, Immunomedics/Gilead, Lilly, Merck, Nanostring, Nektar, Novartis, Odonate, Pfizer, Sanofi, Seattle Genetics; consulant: 4D Pharma, ARC Therapeutics, AstraZeneca, Athenex, BeyondSpring Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb, Certara, Chugai, CytomX, Daiichi Sankyo, Eisai, Ellipses Pharma, Genentech, Immunomedics/Gilead, Kyowa Kirin Pharmaceuticals, Lilly, Mersana, Novartis, OncoPep, OncoSec, OncXerna, Pfizer, Puma, Reveal Genomics, Samsung Bioepsis, Sanofi, Seattle Genetics, Zentalis, Zetagen, Zymeworks.